October 25, 2022
4 min watch
Source/Disclosures
Chamberlain J, et al. Neurogenetics and gene therapy. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Disclosures:
Chamberlain reports some of the gene therapy vehicles discussed are currently the subject of patent applications.
CHICAGO – Jeffrey Chamberlain, PhD, professor of neurology at the University of Washington, discussed types of gene therapy as a possible treatment for muscular dystrophy at ANA 2022.
“One of the biggest issues is, how do you deliver a gene back to muscles?” Chamberlain said. “Currently, [adeno-associated virus] vectors are the only known method to efficiently deliver genes body-wide to muscle.”
Chamberlain said that there are several clinical trials underway for the study of gene delivery. However, he said the results “are not perfect.”
Read more about
